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1. Introduction
Androgens are the group of hormones that promotes the development and maintanance of
male sex characteristics and are largely responsible for the developmental changes that oc‐
cur during puberty and adolescence. The most important androgen secreted is testosterone.
It is both an active hormone and a prohormone for the formation of a more active androgen,
the 5a-reduced steroid dihydrotestosterone (DHT), which acts in the cell nucleus of target
tissues, such as skin, male accessory glands, and the prostate, exerting predominantly an‐
drogenic, but also anabolic, effects. [75]. Testosterone is 19-carbon steroid formed from cho‐
lesterol via a series of enzimatic reactions in the Leydig cells of the testes and adrenal cortex
in men, while in woman the primary site is the adrenal cortex [33]. Testosterone secretion is
under the control of luteinizing hormone (LH) which is produced by the pituitary gland.
Synthesis and release of LH is under control of the hypothalamus through gonadotropin-re‐
leasing hormone (GnRH) and inhibited by testosterone via a negative feedback mechanism
[43]. Testosterone basic structure is composed of 3 cyclohexane rings and 1 cyclopentane
ring with a methyl group at positions 10 and 13 [67]. Healthy men produce approximately
4.0–9.0 mg of testosterone per day with blood concentrations ranging from 300 to 1,000 ng/
dL-1 (10.4–34.7 nmol/L-1), while blood concentrations for females range from 15 to 65 ng/dL
-1 (0.5–2.3 nmol/L-1) [43]. Testosterone is carried to target cells through the bloodstream ei‐
ther free (only about 1–3% of circulating testosterone) or bound to a carrier protein. Most of
the circulating testosterone (~50–60%) is bound with high affinity to sex hormone-binding
globulin (SHBG), while a smaller fraction (40–50%) is bound loosely to albumin [49]. After
reaching target cell, testosterone passes the membrane by simple diffusion becouse of its
small molecular weight and liphophilic nature, [8]. Once entering the cell, the effects of tes‐
tosterone in males and females occur by the way of two main mechanisms: genomic action
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by activation of the androgen receptor (directly or as DHT - 5 alpha dihydrotestosterone),
and nongenomic action by conversion to estradiol and activation of certain estrogen recep‐
tors [19]. In u nutshell, the binding of the testosterone to its receptor produces conformation‐
al changes that result in the formation of a “transformed” or activated receptor with high
affinity for specific DNA-binding site. This consequently recruits co-activators or co- re‐
pressors of gene expression [4]. Several non-genomic mechanisms appear to be involved re‐
garding testosterone, including mediation by the membrane-bound sex hormone-binding
globulin receptor and also a putative G-protein-coupled receptor that androgens directly
bind with, as well as through stimulation of nonreceptor tyrosine kinase c-SRC. In adittion,
testosterone administration has been shown to rapidly increase intramuscular calcium and
extracellular signal–regulated kinase 1/2 (ERK 1/2) phosphorylation, involved in muscle hy‐
pertrophy [26]. Testosterone is metabolically inactivated in the liver and excreted in urine
thru conjugation reactions, act to couple the anabolic steroid or its metabolite with glucuron‐
ic acid or sulfate [65].
Testosterone effects on body tissue are far more complicated than its production and secre‐
tion, directly or indirectly through its metabolites influencing the development and function
of practicaly every organ in the body [51, 52]. Its complex biological actions regulates the de‐
velopment of the male phenotype, secondary sexual characteristics that transforms boys into
men during embryonic life and at puberty respectively and regulates many physiological
processes in the adult male including protein metabolism, sexual and cognitive functions,
erythropoesis, plasma lipids and bone metabolism [11, 74]. In general, testosterone has mas‐
culinizing (growth of the male reproductive tract and development of secondary sexual
characteristics) and anabolic effects (nitrogen fixation and increased protein synthesis with
consequent increase in sceletal muscle mass and strength). Anabolism is defined as any state
in which nitrogen is differentially retained in lean body mass through the stimulation of
protein synthesis and/or a reduction in protein breakdown [54].
Medical interest in testosterone started in the mid-1930s after the chemical structure was
published, and was largely based on its anabolical effect. Shortly after its synthesis, oral and
injectable testosterone preparations become available to the medical community [77], with
early studies mainly exploring its effects for treating hypogonadism and impotency [43].
However, it has been shown early that testosterone itself is relatively ineffective when taken
orally or injected in an aqueous solution because it is susceptible to relatively rapid break‐
down by the liver before it can act on the target organ. About 90% of the hormone is already
metabolized before it reaches the bloodstream. Testosterone has a short free-circulating half-
life due to its rapid metabolism by the cytochrome P450 family of hepatic isoenzymes [3]. In
adittion, it has a therapeutic index of 1 meaning there is similarity in the proportion between
the anabolic and androgenic effects. Consequently, the chemical structure of testosterone
has been modified to cirkumvent this problem. It should be noted, however, that no synthet‐
ic steroid has completely eliminated the androgenic effect, which is partly due to the fact
that the androgenic and anabolic effects differ only in location and not in the mechanism of
the steroid hormone action. Since its discovery, numerous derivatives of testosterone have
been synthesized, in order to delay the degradation of steroids, to maintain blood levels of
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the drug for prolonged time periods, to intensify the overall effects of the compound while
limiting androgenic effects and overpower the catabolic pathways by supplying the drug in
mass quantity. Slight biochemical modifications has been proved to alter biological activity
by modifying presystemic metabolism, half-life, AR binding affinity, AR stabilization, coac‐
tivator recruitment, nuclear translocation, DNA binding affinity, and tissue selectivity. One
of the first changes made to the testosterone molecule was the addition of a methyl or ethyl
group to the 17-alpha- carbon position (called alkylation), which inhibits the presystemic
metabolism of the molecule, substantialy extending its half-life and making it active when
administered orally [43]. Beyond alkylation, one more major modifications can be destuin‐
guished, esterification of testosterone and nortestosterone at the 17-beta- position makes the
molecule more soluble in lipid vehicles used for injection and slows the release of the inject‐
ed steroid into the circulation [6]. Those synthetic compounds, which are similar in chemical
structure to testosterone, are collectively called anabolic steroids.
The effect of testosterone and its derivatives on muscle mass gains has not been lost on the
medical community. The therapeutic importance of anabolic steroids in treatment of catabo‐
lic conditions was recognized as early as in the 1950s, after which an enormous number of
steroids were synthesized and tested for potency. For example, metandienone and stanozo‐
lol, two of the most frequently used anabolic steroids, were synthesized in 1955 and 1959,
respectively [65]. Today, there are more than 100 varieties of anabolic steroids that have
been developed, but only a limited number have been approved for human use. The com‐
mon anabolic steroids are shown in Table 1.
Oral Agents
17- alpha-alkyl derivatives
Injectable Agents
17 beta-ester derivatives
Methandrostenolone (dianabol) Testosterone esters: blend, cypionate, enanthate,heptylate, propionate
Methyltestosterone (android) Nandrolone esters: decanoate (deca-durabolin) ,phenpropionate
Oxandrolone (anavar) Boldenone
Oxymetholone (anadrol) Methenolone
Stanozolol (winstrol) Trenbolone
Fluoxymesterone (halotestin) Stanozolol
Danazol Dromostanolone
Ethylestrenol (maxibolin, oraboline)
Table 1. Anabolic Steroids in Common Use
As can be seen in Table 1., there are two major classes of AS used, based on the route of ad‐
ministration: Oral and parenteral AS preparations. Oral preparations are synthesized in or‐
der to offer protection to the molecule when it becomes exposed to the strong acid solutions
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found in the stomach, and when it contacts the enzymic mechanisms of the liver. Protection
is conferred by the substitution of a methyl (CH3) or ethyl (C2H5) group for the H attached
to the carbon atom (C) on the cyclopentane ring structure, in position 17. The 17α-alkylated
steroids prevent deactivation by the first-pass metabolism by sterically hindering oxidation
of the 17β-hydroxyl group. The effectiveness of 17- alkylated AS is due to a slower hepatic
inactivation that occurs with unmodified hormone. Oral activity can also be obtained thru
attachment of a methyl group at C-1, but these anabolic steroids are considered to be rela‐
tively weak in pharmacological activity. Oral preparations are proved to have a short half-
life so, in order to maintain the appropriate blood concentration the drug must be taken
several times a day. Parenteral preparations do not require a 17a- alkyl group, but the 17p-
hydroxyl group is esterified with an acid moiety to prevent rapid absorption from the oily
vehicle. Once an AS-ester hits the bloodstream, enzymes called esterases rapidly split off the
fatty acid. A long fatty acid makes the AS more lipid-soluble and it will disperse from the
injected oil depot more slowly (days to weeks). The duration of action of the parenteral ste‐
roids depends upon the chain length of the acid moiety and the formulation, with general
tendency that the longer the chain length, the more slowly the preparation is released into
circulation. Generaly, parenteral AS dosing require intramuscular dosing once every 2 to 12
weeks, depending on the carboxylic acid groups added [9].
Pharmaceutical companies initially developed these synthetic analogues of testosterone in
order to treat catabolic medical conditions. A number of clinical studies have shown that the
potent anabolic effects of anabolic steroids could be used to: restore hormone levels in hypo‐
gonadal men, thereby increasing fat-free mass, muscle size and strength, and bone density;
improve mood and alleviate depression; increase body weight, muscle mass, and strength in
eugonadal patients with secondary wasting syndromes, such as infection with HIV when
maintaining lean body mass may be beneficial for long-term survival; and augment muscle
mass in older men and prevent age-related sarcopenia that contributes to frailty and falls
[28]. The anabolic activity of testosterone derivatives is primarily manifested in its myotro‐
phic action, which results in greater muscle mass and increased strength. This, in adittion to
the stimulatory effects of androgens on the brain, which frequently result in a feeling of eu‐
phoria, increased aggressive behavior, and diminished fatigue, has led to the widespread
use of anabolic steroids by both profesionnal and recreational athletes. Athletes use them to
enhance performance, driven by the potential financial and other rewards that may come
with sporting success. In adittion, recreational users of anabolic steroids are the most rapid‐
ly growing group, and their aim is to combat ageing and obesity as well as to improve phys‐
ical appearance in order to receive the admiration that modern society give to a ‘perfectly
toned’ body. However, anabolic steroids have been associated with a range of transient side
effects, which can be divided into several categories, including cardiovascular, hepatic, en‐
docrine/reproductive, behavioral, dermatologic, and injection related. Data from larger ob‐
servational studies suggest that the majority (88%-96%) of anabolic steroid users experience
at least 1 minor subjective side effect [14]. Studies on the benefits and risks of testosterone
are ongoing, but seem to consistently produce mixed results. As therapeutical use becomes
more common, its controversy in the sports world has lead to considerable public outcry
against its use. In this chapter we will considers available data on anabolic steroid applica‐
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tion in sport & exercise with special attention on three distinct aspects of AS usage by pro‐
fessional and recreational atheletes: effects on sport performance, adverse effects and
legislative considering its usage.
2. Anabolic steroids and sport performance
Soon after the development of synthetic steroids, these drugs were discovered by athletes
for their muscle building and performance enhancing properties. According to anecdotal re‐
ports, it has been rumored, but never documented, that some German athletes were given
testosterone in preparation for the 1936 Berlin Olympics. West Coast bodybuilders began ex‐
perimenting with testosterone preparations in the late 1940s and early 1950s. It appears that
the use of testosterone and its synthetic derivatives began to infiltrate sports during the
1950s, with even government instituted-top secret program implementation that provided
for the administration of androgens and other doping products to male and female athletes
during later period [43]. In the early 1950s, the first suspicion that anabolic steroids were ac‐
tualy administered in order to improve sporting performance came with allegation that so‐
viet weightlifters were adminestering AS to gain strength [71] News of the efficacy of these
drugs apparently spread during the early 1960s to other strength-intensive sports, from the
throwing events of track and field to football. Throughout the 1960s, the use of anabolic ste‐
roids increased so dramatically that In 1969 John Hendershott, the editor of Track & Field
News, called these drugs the ‘‘breakfast of champions’’ [40]. Although the International
Olympic Committee banned use of anabolic agents in 1964, the practice spread and proba‐
bly reached its pinnacle in the athletic programs in Germany during the 1970s [78]. Their use
nowdays is most common among weight lifters and heavy throwers, nevertheless almost all
types of athletes whose event requires explosive strength, in- cluding football players,
swimmers and track and field athletes, have been known to use steroids. The level of steroid
use appears to have increased significantly over the past three decades [46], and is no longer
limited to elite athletes or to men. Although competitive athletes report higher rates of ste‐
roid use, a significant number of recreational athletes and non-athletes appear to be using
these drugs, probably to “improve” their appearance.
The effects of testosterone and its derivatives on human performance have been extensively
studied. As early as 1889, Brown- Sequard, reported increases in muscular strength, mental
abilities, and appetite as a qonsequence of self-injections of testicular extracts from guinea
pigs and dogs [22]. Largely based on this work, two of the Austrian physiologist Oskar Zoth
and Fritz Pregl began to investigates the effects of injections of testicular extracts on muscle
strength and athletic performance [42]. Zoth and Pregl injected themselves with extracts
from bull testicles and reported increased strength of their middle fingers. Although it is
likely that these results were placebo effects, Zoth may be the first person to suggest inject‐
ing steroids in an attempt to increase performance [41].
Since the 1960s many researchers have investigated performance-enhancing effects of ana‐
bolic steroid administration in professional and recreational athletes. The strength gains and
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other purported performance-enhancing benefits commonly attributed to anabolic steroid
use in professional and recreational athletes were challenged and often discounted by early
medical studies. Upon further examination of initial studies it become apparent that most of
them had major flaws in design, such as lack of control groups and a double-blind proce‐
dure, the presence of confounding factors (e.g., differences in level of exercise and in moti‐
vation), and inappropriate statistical techniques [12, 34]. In adittion, most of them have used
steroid doses 5–20 times lower than those used by many athletes. As it has been proved that
anabolic steroid administration increases lean body mass, muscle mass, and maximal volun‐
tary strength in a concentration-dependent manner [13], it is no surprise that early investiga‐
tions were usually unable to determine any substantiall effect of AS administration on
human performance..
Considerable amount of researh investigating ergogenic effects of anabolic steroid adminis‐
tration were conducted before and during 1980s, with conflicting findings presented. Sever‐
al studies did not report ergogenic effects of anabolic steroids on muscle strength or
performance. Fowler and coworkers [31] examined the intake of 20 mg/day for 16 weeks of
methyl androstenolone acetate to 47 men (10 rugby players and 37 untrained students) who
either did not exercise or exercised 30 min/day, 5 days a week and reported no significant
difference between groups in muscle size, body weight, or isometric strength. Weiss and
Muller [72] examined the intake of 10 mg of Metandienone for 17 days in 32 high school stu‐
dents and did not report any enhancment of strength measured during arm extension. Cas‐
ner and coworkers [18] examined the intake of 6 mg/days of Stanozolol in 27 young man
conducting the weight training 3 d/wk and reported no ergogenic effects of anabolic steroid
on leg, arm and trunk isometric strength. Golding and coworkers [35] administered 1o
mg/day of Metandienone in three consecutive 4-week cycles interpersed with 1 week of no
adminitration in 40 experienced weightlifters and reported no significant improvements in
strength parameters. Stromme and coworkers [67] examined the intake 75 mg/day of mes‐
terolone for 4 weeks and 150 mg/day for the subsequent 4-week period in 21 students en‐
gaged in weight training sessions and reported that anabolic steroids did not enhanced
strength parameters measured during different flexion and extension exercises. Crist and
coworkers [21] administered 100 mg/week of testosterone cipionate or placebo (3 weeks
each) and reported no significant difference was observed in several isokinetic flexion/exten‐
sion exercises between anabolic steroid and placebo conditions. Loughton and Ruhling [55]
examined the intake of 10 mg/day of Metandienone for 3 weeks and 5 mg/day for 3 more
weeks concomitant with weight training and running program and reported greater weight
gains in the androgen group but nonsignificant interactions in strength performance.
Considerable amount of research during this period did report significant ergogenic effects
of anabolic steroid administartion in professional or recreational athletes. Johnson and
O’Shea [45] examined administration of 10 mg/day of Matandienone during the last 3 weeks
of 6 week training programme to half of the 24 subjects. They reported reported significantly
greater gains in isometric strength and 1 repetition maximum (1RM) squat in the steroid
group. Next year, O’Shea and Winkler [60] reported enhanced muscle strength after 6 weeks
of strength training with concomitant use of 10mg/day of Oxandrolone in well-trained
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weightlifters. Finaly, O’Shea [61] administered 10 mg/day of Dianabol for 4 weeks to half of
the sample consisted of 18 weightlifters and reported significantlly higher increase in squat
and bench press strength in the steroid group. Several other authors reported similar results
obtained on the sample of professional or recreational athletes administering Metandienone
in the same quantity as O’Shea in previously mentioned study with a similar duration of
studies [15, 44, 12]. Moreover, although most research has focused on absolute strength de‐
termined by one repetition maximum or isokinetic strength, one study tested the effects of
anabolic steroid use on sport performance. Rademacher and coworkers.[64] reported that in
male canoeists, 6 weeks of Oral-Turinabol administration improved strength and perform‐
ance measured by canoe ergometry with 6% and 9%, respectively.
Although study designs improved during 1970s and 1980s and in some cases were more re‐
alistic than previously, it could be speculated that the first rigorous study of the perform‐
ance-enhancing effects of anabolic steroids was not carried out until 1996. In this seminal
study by Bhasin and coworkers [11] supraphysiological dosages of anabolic steroid (testos‐
terone enenthate- 600mg/week) were administered to forthy eugonadal men between 19 and
40 years old (within 15% of their ideal body weight) who were or were not engaged in
strength training programme. Subjects sample was randomly assigned to one of four
groups: placebo but no exercise; testosterone but no exercise; placebo plus exercise; testos‐
terone plus exer- cise. The subjects who were administered both anabolic steroid and
strength training were found to gained significantly greater muscle mass (+6 kg), fat free
mass (6,1 kg), quadriceps and biceps area (+1174 mm2 and +501mm2, respectively) as well
as 1-RM bench and press squats (+22kg and +38 kg, respectively) when compared to other
groups. Moreover, injectable steroid has been shown to improve strength even without a
concomitant resistance-training programme! The investigation suggests that supraphysio‐
logical doses of anabolic steroids stimulate significant alterations in muscle size and muscle
strength, especially when taken in conjunction with a progresive resistance training pro‐
gramm. Several other studies during and after this period further examined anabolic steroid
use in professional or recreational athletes, with continuous reports that anabolic steroid
users had greater mass than nonusers and that longitudinally anabolic steroids increased
lean body mass, muscle strength and performance. Subsequent work showed that increases
in fat-free mass, muscle size, and strength are highly dose-dependent and correlated with
serum testosterone concentrations [12, 76] It has been shown that improvements in body
physique were greatest at higher doses, for example, at least 125 mg/week1 [43]. It appears
that the most common benefit of anabolic steroid use is an increase in muscle mass and/or
strength. It also appears that this effect may demonstrate a dose-response relationship, i.e.
the more anabolic steroid used, the greater the effect on muscle mass and strength [13].
However, higher dosages are correlated with higher incidence of adverse effects of anabolic
steroid use in humans, which we will discuss further in the next section.
Information on doses and modes of administration of AS used by athletes to increase their
performance is relatively sparse. It is known that steroid regimens favored by professional
and recreational athletes differ markedly from those used clinically. Athletes use supraphar‐
macological doses that range from 10–100-fold above normal levels [75]. Steroids are usually
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used in the off-season, when athletes are strength trained and when use is least likely to be
detected. Typically, they take androgens in cycles of 4-12 weeks, with a period of abstinence,
knowns as a “drug-free holiday” period of varying duration. The purpose for the holiday is
to minimize side effects, promote recuperation of various hormonal systems, and avoid de‐
tection during competition. Although the length of each cycle is quite variable (ranges from
1 to 728 weeks), the median cycle length is reported to be 11 weeks [43]. After this period,
athletes often reported a plateau in subjective benefits, which might be explained by steroid
receptor saturation and downregulation. In adittion, most athletes use “stacking” regimens
that involve taking multiple agents simultaneously, and/or a pyramid their doses in cycles
of 6 to 12 weeks. At the beginning of a cycle, one starts with low doses of the drugs being
stacked and then slowly increases the doses. In the second half of the cycle, the doses are
slowly decreased to zero. Athletes tend to use both oral and parenteral (injectable) com‐
pounds, with typical regimen of 3 agents being reported [43].
3. Adverse effects of anabolic steroids
For clinical purposes, the administration of anabolic steroids can be of therapeutic benefit
and reasonably safe. By contrast,  for the purposes of enhancing performance in sport or
for cosmetic purposes, usually because it is a clandestine activity, the athletes and body‐
builders are making subjective decisions regarding the effect these steroids are having on
their health. The incidence of complications associated with the nonmedical use of anabol‐
ic  steroids as performance-enhancing drugs is  unclear because the denominator of  drug
use in athletes is not well defined. Data from larger observational studies [27] suggest that
the majority (88%-96%) of anabolic steroid users experience at  least  1 subjective side ef‐
fect. Since anabolic steroids have effects on several organ systems, a myard of side effects
can be found. Consequently, the undesirable effects arising from anabolic steroid adminis‐
tration have been extensively  studied and reviewed [37,  66,  50].  Hovewer,  it  should be
recognized that giving super high doses of anabolic steroids to induce side effects for ethi‐
cal reasons cannot be studied in laboratory settings, with data defining cumulative effects
caused by stacking remains speculative and derived from case reports and medical litera‐
ture from lower level doses. Nevertheless, summarising the literature, it can be concluded
that the potential adverse effects of anabolic steroid use can be divided into several cate‐
gories,  including  cardiovascular,  hepatic,  endocrine/reproductive,  psychological,  muscu‐
loskeletal and dermatologic related.
In both the medical and lay literature one of the principal adverse effects generally associat‐
ed with anabolic steroid use is the increased risk for myocardial infarction. Several case re‐
ports document myocardial infarction and stroke in 20- to 30-year-old weightlifters that
used anabolic steroids, which can be attributed to the increased platelet count and platelet
aggregation that occurs in people who abuse anabolic steroids [30]. Steroids also cause hy‐
pertrophy of the myocardium, which also increases the likelihood of arrhythmias, sudden
death, systolic and diastolic hypertension [44]. Anabolic steroid abuse cause harmfull
changes in lipoprotein profile with increased LDL levels (by 40-50%) and decreased HDL
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level (40-70%). The decline in HDL are most evident with the use of oral administration ana‐
bolic steroids with drugs such as stanazolol, oxymetholone and metandienone and can often
be seen in a few days after the initiation of anabolic steroid use [70]. High doses of AS may
increase the risk of atherosclerosis and thrombosis through their effects on clotting factors
and platelets and induce vasospasm or myocardial injury because of effects on myocardial
cells [56]. Finaly, high dose AS use is found to induce systemic hypertension, with magni‐
tude and incidence of hypertension likely related to dosage and to the type of AS used [17]
Cardiovascular Myocardial infarction; Myocardium hypertrophy; Increased LDL and decreased HDL levels;
Thrombosis; Elevated blood pressure
Hepatic Increased risk of liver tumors and liver damage
Endocrine/reproductive Male: Testicular atrophy; Oligospermia; Gynecomastia; Prostatic hypertrophy
Female: Alterations of pubic hair growth, Clitoral hypertrophy, Menstrual irregularities;
Breast atrophy
Psychological Mood swings; Aggressive behavior; Depression; Psychosis
Musculoskeletal Increased risk of musculotendious injuries
Dermatological Acne; Alopecia
Table 2. Adverse effects of anabolic steroid use.
Liver function disturbances and diseases in AS-abusing athletes have been of great concern
since animal studies have clearly shown the deleterious effects of AS on the liver. In adit‐
tion, liver cancer occurrence in non-athletic populations being treated with testosterone for
aplastic anemia has been reported [58]. Elevations in levels of liver enzymes (aspartate ami‐
notransferase, alanine aminotransferase, and lactate dehydrogenase) are regularly reported
in athletes who use steroids. Several case reports have associated the occurrence of liver dis‐
orders such as subcellular changes of hepatocytes, impaired excretion function, cholestasis,
peliosis hepatis and hepatocellular hyperplasia, and carcinomas in with the abuse of AS in
young, healthy athletes. Hepatic dysfunction is most commonly associated with the 17-al‐
pha alkylated steroids, with no cysts or tumors have been reported in athletes using 17β-
alkylated steroids. Thus, evidence appears to indicate that the risk for hepatic disease from
anabolic steroid use may not be as high as the medical community had originally thought
although a risk does exist especially with oral anabolic steroid use or abuse.
Use of steroids in men decreases levels of luteinizing hormone and follicle-stimulating hor‐
mones, which leads to decreased endogenous testosterone production, decreased spermato‐
genesis, and testicular atrophy. The testicular atrophy and the oligospermia usually resolve
after discontinuation of the drugs, but the count and morphology of the sperm may be ab‐
normal for up to 6 months [23]. Prostatic hypertrophy, priapism, and, rarely, carcinoma of
the prostate can be associated with steroid use [72]. When AS levels are elevated, they un‐
dergo aromatization, being converted to estrogens and qonsequently can produce (i)reversi‐
ble gynecomastia. Use of anabolic steroids in women, is not only associated with menstrual
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abnormalities but with masculinizing effects as well. Female athletes reported the develop‐
ment of acne vulgaris, changes in libido and alterations of the voice as the most pronounced
acute effects, with long-term AS administration proved to induce loss of hair, alterations of
pubic hair growth, clitoral hypertrophy, menstrual irregularities and a reduction of the
breasts [43].
Hystoricaly, low doses of AS have been used to treat depression and melancholia either as
monotherapy or as adjunct to standard treatment, but misuse of these agents has added a
new term to the drug lexicon “roids rage” Anecdotal reports of ‘‘roid rage,’’ have attracted a
great deal of attention in scientific community. Pope and Katz [63] noted that anabolic ste‐
roids produce clear psychiatric effects, particularly in individuals using excessive doses
(more than 1,000 mg/wk) of these compounds and stacking the drugs. Some individuals
may experience mental status and behavioral changes with anabolic steroid use iincluding
irritability, aggressivity, euphoria, grandiose beliefs, hyperactivity, and reckless or danger‐
ous behavior [20]. Other presentations have included the development of acute psychoses,
exacerbation of tics, and the development of acute confusional states [38]. Kouri and cow‐
orkers [53] reported that administration of supraphysiological doses (600 mg weekly) of tes‐
tosterone enanthate to healthy young men was associated with a significant increase in
aggressive responses than placebo administration. A high proportion of women athletes us‐
ing high doses of androgens report symptoms of hypomania and depression, rigid dietary
practices, and dissatisfaction and preoccupation with their physique [36].
Some scientists believe that there is an increased risk of musculotendious injuries with ste‐
roid use in humans. It has been speculated that tendons may not increase in strength as
muscles do and, when subject to increased intensity and frequency of training, may be at
higher risk for rupture [7, 66]. However, although the studies in mices and rats have sug‐
gested that anabolic steroids may lead to degeneration of collagen and/or decrease in col‐
lagen  synthesis  [48,  57],  the  response  in  humans  has  been  less  clear.  Ultrastructural
analysis  on ruptured tendons from anabolic  steroid users have shown that anabolic  ste‐
roids did not induce any ultrastructural collagen changes that would increase the risk of
tendon ruptures [29].
Acne is one of the more common side effects associated with anabolic steroid administra‐
tion, and it is a result of the androgenic stimulation of the sebaceous glands. One study re‐
ported that 43% of users experienced acne as a consequence from androgen use [62]. They
appear to disappear upon cessation of anabolic steroids administration. Finaly, temporal
hair recession and alopecia can be seen in men and women using anabolic steroids for ex‐
tended periods of time.
Summarising the literature, it can be concluded that anabolic steroid users and potential
users should be aware that many of the adverse effects of anabolic steroids are present and
may exert profound effects on their health. More so, studies have been able to link anabolic
steroids to many of the serious adverse effects listed. It would seems logical that the axiom,
particularly among professional and recreational athletes who can use excessively large
amounts of steroids, that the ‘more you take, the more you grow’ should be accompanied
with ‘the more you may damage your health’.
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4. Anabolic steroids and doping regulations
The use of substances to enhance performance in sports is a long standing phenomenon. In
1928, the International Amateur Athletics Federation (IAAF), became the first International
Sport Federation to ban the use of stimulating substances. Many other federations followed
suit, but restrictions remained ineffective because no tests were made. Meanwhile the prob‐
lem was made worse by synthetic substances developed in the 1930s and in growing use for
doping purposes by the 1950s. The death of a Danish cyclist at the 1960 Olympic Games in
Rome put pressure on sports authorities to work more aggressively to deter doping follow‐
ing the confirmation of amphetamine in biologic fluids collected at autopsy on this athlete
[32]. The death of cyclist Tom Simpson, during the Tour de France, following the use of am‐
phethamines, further catalysed the situation and in 1966, the first doping tests were intro‐
duced for international cycling and football. With the increasing use of performance-
enhancing drugs and several high-profile deaths of athletes from various sports, the
International Olympic Committee (IOC) established a medical commission in 1967 with its
primary goal to create a list of prohibited substances and methods [32]. The initial goal of
putting in place an antidoping structure was rapidly widened to encompass the following
three fundamental principles: (1) protection of the health of athletes, (2) respect for both
medical and sports ethics, and (3) equality for all competing athletes. In the same year, the
International Olympic Committee drew up its first list of prohibited substances, and drug
tests were first introduced at the 1968 Olympic Games in Mexico. At that time, many sports
governing bodies such as UCI (cycling) and FIFA (football) based in Europe established
rules regarding the use of drugs in sports.
At the 1988 Olympic games in Seoul, Canadian sprinter and then current world’s fastest
man Ben Johnson tested positive for stanozonol [16]. This positive test sent shock waves
through the sporting community, resulting in the U.S. government passing the Anti-Drug
Abuse Act, which made it illegal to distribute or possess androgens. Additionally, the IOC
expanded the banned substance list to include diuretics, such as probenecid, and other
products typically used to mask androgens use. In 1990, the U.S. government went a step
farther when it passed the first Anabolic Steroid Control Act and inserted 27 steroids, along
with their muscle building salts, esters, and isomers as class III drugs and simple possession
could result in prison time [43]. Today, under the US Federal Controlled Substances Act,
anabolic steroids are classified as Schedule IlI substances, which places them in the same
category as amphetamines, methamphetamines, opium and morphine. Possession of any
Schedule I substance is a felony offense with punishment up to five years in prison. If one
sells steroids, or possesses enough to evidence an intent to sell, he/she faces up to five years
in prison and a $250,000 fine.
During a raid at 1988 Tour de France, police found a large number of prohibited medical
substances. This highly publicized scandal highlighted the need for an independent interna‐
tional agency that would establish unified standards for antidoping work and coordinate
the efforts of sports organizations and public au thorities. The IOC took the initiative and
convened the World Conference on Doping in Sport held in Lausanne, Switzerland in Feb‐
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ruary 1999. Following the proposal of the Conference, the World Anti-Doping Agency (WA‐
DA) was established on November 10, 1999.
According to surveys and media reports, the illegal use of AS to increase muscle size and
strength is widespread [28]. Current estimates indicate that there are as many as three mil‐
lion AS users in the United States alone and that 2.7–2.9% of young American adults have
taken AS at least once in their lives [59]. Interviews of high-school students in several Euro‐
pean countries reveal that 1–5% have used AAS [69], with similar figures found for high-
school-aged students from Canada, Australia and South Africa [5]. Anabolic steroids are
used for performance enhancement across the spectrum of athletes, from the elite to rising
young men and women in youth programs and high school. Increasing numbers of athletes
are nowdays relying on anabolic steroids to enhance their strength, endurance, and per‐
formance, despite the knowledge of the potentially serious adverse consequences these
agents can have. According to the WADA statistics, AS are the most frequent adverse ana‐
lytical findings for Olympic sport athletes, in-and out-of- competition. In 2003, the World‐
wide Out-of-Competition Testing Program conducted by the World Anti-Doping Agency
detected 23 positive cases among a total of 5004 samples obtained (4229 urine, and 775 blood
samples), with three refusals to provide a sample. The prevalence values for AS use among
other groups of exercisers and athletes range between 6.2 and 38.4%. However, the reported
response rates were at best 66%, rendering these findings highly unreliable [69]. In 2006, the
33 WADA accredited laboratories in 29 countries reported 1 966 (45.4%) of the 4 332 adverse
analytical findings were anabolic steroids. It is likely that the AS use among athletes from
high school to Olympics caliber is on the rise and gaining momentum, according to individ‐
uals closest to the issue [10].
Nowdays, many countries are on the way to strengthening the laws against possession and
use of AS and now consider these drugs as equivalent to narcotics. An important concern is
the ease with which banned substances can be obtained by athletes and the public. The re‐
sults of studies by Eriksson [24,25] show the effect of AS on muscle fibres lasts much longer
than believed, which suggests that athletes using anabolic agents should be disqualified for
longer than 2 years. His histological observations is highly in accordance to an old observa‐
tion in East Germany that “androgenic initiation” has long-lasting effects. Anabolic steroids
are controlled substances and are illegal to possess or sell without a prescription for a legiti‐
mate medical condition by the prescribing physician. Androstenedione, norandrostenedione
and other similar prohormones, at one time available over the counter as dietary supple‐
ments, are now defined as controlled anabolic steroids. Due to serious health risks, non-
medical use of anabolic steroids is nowdays banned by most major sports organizations.
International Olympic Comitee banned the use of anabolic steroids in 1976. In addition, ana‐
bolic steroids are on the WADA (World Anti-Doping Agency) prohibited list, the annual
publication of all illegal performance-enhancing substances.
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